• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于线粒体的眼病治疗的现状与未来。

The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease.

机构信息

Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.

Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.

出版信息

Transl Vis Sci Technol. 2021 Jul 1;10(8):4. doi: 10.1167/tvst.10.8.4.

DOI:10.1167/tvst.10.8.4
PMID:34232272
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8267180/
Abstract

Mitochondria are viable therapeutic targets for a broad spectrum of ocular diseases.

摘要

线粒体是广泛眼部疾病的可行治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ab/8267180/5d887bfe2b5a/tvst-10-8-4-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ab/8267180/5d887bfe2b5a/tvst-10-8-4-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1ab/8267180/5d887bfe2b5a/tvst-10-8-4-f001.jpg

相似文献

1
The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease.基于线粒体的眼病治疗的现状与未来。
Transl Vis Sci Technol. 2021 Jul 1;10(8):4. doi: 10.1167/tvst.10.8.4.
2
Ocular Therapeutics: Drug Delivery and Pharmacology.眼部治疗学：药物递送与药理学
Mol Pharm. 2016 Sep 6;13(9):2875-6. doi: 10.1021/acs.molpharmaceut.6b00703.
3
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.眼科疾病治疗学：眼部疾病药物的设计与传递。
J Med Chem. 2020 Oct 8;63(19):10533-10593. doi: 10.1021/acs.jmedchem.9b01033. Epub 2020 Jun 2.
4
New ocular therapeutics: a view from the patenting perspective.新型眼部治疗药物：专利视角下的审视
IDrugs. 2007 Jan;10(1):37-41.
5
Targeting mitochondrial function to protect against vision loss.针对线粒体功能以预防视力丧失。
Expert Opin Ther Targets. 2016 Jun;20(6):721-36. doi: 10.1517/14728222.2015.1134489. Epub 2016 Jan 13.
6
Ocular therapeutics.眼部治疗学
Trans Pa Acad Ophthalmol Otolaryngol. 1976 Spring;29(1):22-34.
7
A physician looks at ocular therapeutics.一位医生审视眼部治疗学。
Trans Ophthalmol Soc U K (1962). 1964;84:487-517.
8
Delivery of therapeutics for deep-seated ocular conditions - status quo.深部眼疾治疗药物的递呈 - 现状。
J Pharm Pharmacol. 2018 Aug;70(8):994-1001. doi: 10.1111/jphp.12924. Epub 2018 Apr 19.
9
Ocular therapeutics.眼科治疗学
Clin Exp Optom. 2004 Mar;87(2):124-5. doi: 10.1111/j.1444-0938.2004.tb03160.x.
10
Reactive Oxygen Species and the Aging Eye: Specific Role of Metabolically Active Mitochondria in Maintaining Lens Function and in the Initiation of the Oxidation-Induced Maturity Onset Cataract--A Novel Platform of Mitochondria-Targeted Antioxidants With Broad Therapeutic Potential for Redox Regulation and Detoxification of Oxidants in Eye Diseases.活性氧与衰老眼睛：代谢活跃的线粒体在维持晶状体功能及氧化诱导的成熟期白内障发生中的特定作用——一种具有广泛治疗潜力的线粒体靶向抗氧化剂新平台，用于眼部疾病中氧化还原调节和氧化剂解毒。
Am J Ther. 2016 Jan-Feb;23(1):e98-117. doi: 10.1097/MJT.0b013e3181ea31ff.

引用本文的文献

1
Preservation of Mitochondrial Function by SkQ1 in Skin Fibroblasts Derived from Patients with Leber's Hereditary Optic Neuropathy Is Associated with the PINK1/PRKN-Mediated Mitophagy.SkQ1对Leber遗传性视神经病变患者来源的皮肤成纤维细胞线粒体功能的保护作用与PINK1/PRKN介导的线粒体自噬相关。
Biomedicines. 2024 Sep 4;12(9):2020. doi: 10.3390/biomedicines12092020.
2
Mitochondria in Retinal Ganglion Cells: Unraveling the Metabolic Nexus and Oxidative Stress.视网膜神经节细胞中的线粒体：揭开代谢关联和氧化应激之谜。
Int J Mol Sci. 2024 Aug 7;25(16):8626. doi: 10.3390/ijms25168626.
3
Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma.

本文引用的文献

1
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.Leber 遗传性视神经病变发病 6 个月内接受玻璃体内基因治疗的疗效和安全性。
Ophthalmology. 2021 May;128(5):649-660. doi: 10.1016/j.ophtha.2020.12.012. Epub 2021 Jan 12.
2
Allotopic expression of mitochondrial genes: Basic strategy and progress.线粒体基因的异位表达：基本策略与进展
Genes Dis. 2019 Aug 31;7(4):578-584. doi: 10.1016/j.gendis.2019.08.001. eCollection 2020 Dec.
3
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.
在高血压性青光眼小鼠模型中，烟酸与胞磷胆碱联合给药后视网膜生理功能得以恢复。
Front Med (Lausanne). 2023 Sep 5;10:1230941. doi: 10.3389/fmed.2023.1230941. eCollection 2023.
4
Dysfunctional Autophagy, Proteostasis, and Mitochondria as a Prelude to Age-Related Macular Degeneration.功能失调的自噬、蛋白质稳态和线粒体作为与年龄相关的黄斑变性的前奏。
Int J Mol Sci. 2023 May 15;24(10):8763. doi: 10.3390/ijms24108763.
5
MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma.MDM2抑制剂介导的线粒体代谢紊乱：视网膜母细胞瘤的一种新型治疗策略。
Front Oncol. 2022 Oct 20;12:1000677. doi: 10.3389/fonc.2022.1000677. eCollection 2022.
单侧基因治疗注射治疗莱伯遗传性视神经病变的双侧视力改善。
Sci Transl Med. 2020 Dec 9;12(573). doi: 10.1126/scitranslmed.aaz7423.
4
AMP-independent activator of AMPK for treatment of mitochondrial disorders.用于治疗线粒体疾病的 AMPK 非依赖性激活剂。
PLoS One. 2020 Oct 14;15(10):e0240517. doi: 10.1371/journal.pone.0240517. eCollection 2020.
5
Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation.携带 m.11778G>A（MTND4）线粒体 DNA 突变的 Leber 遗传性视神经病变患者的视觉结果。
J Neuroophthalmol. 2020 Dec;40(4):547-557. doi: 10.1097/WNO.0000000000001045.
6
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans.自噬激活剂尿石素 A 安全无毒，可诱导人体线粒体和细胞健康的分子特征改善。
Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.
7
A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing.一种细菌胞嘧啶脱氨酶毒素可实现无 CRISPR 的线粒体碱基编辑。
Nature. 2020 Jul;583(7817):631-637. doi: 10.1038/s41586-020-2477-4. Epub 2020 Jul 8.
8
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.玻璃体内注射西罗莫司治疗后部非感染性葡萄膜炎的疗效和安全性：西罗莫司评估双盲葡萄膜炎治疗（SAKURA）计划的研究结果。
Ophthalmology. 2020 Oct;127(10):1405-1415. doi: 10.1016/j.ophtha.2020.03.033. Epub 2020 Apr 3.
9
Mitochondrial Replacement in the Clinic.临床中的线粒体替代
N Engl J Med. 2020 May 7;382(19):1855-1857. doi: 10.1056/NEJMcibr2002015.
10
The Relevance of Oxidative Stress in the Pathogenesis and Therapy of Retinal Dystrophies.氧化应激在视网膜营养不良发病机制及治疗中的相关性
Antioxidants (Basel). 2020 Apr 23;9(4):347. doi: 10.3390/antiox9040347.